Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of IOA-244 in Advanced or Metastatic Cancers
NCT04328844Phase 1Active, not recruiting
- Sponsor
- iOnctura
- Start
- Feb 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of roginolisib in melanoma, Uveal melanoma (UM), myelofibrosis (MF) and 3 more (7 arms), sponsored by iOnctura. Primary endpoint: Treatment-Related Adverse Events at 30 weeks. Started Feb 2020; status: active, not recruiting.
02
Drugs
roginolisib
03
Conditions
melanomaUveal melanoma (UM)myelofibrosis (MF)mesotheliomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04328844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328844.